Literature DB >> 984783

Comparative pharmacokinetics of cefamandole, cephapirin, and cephalothin in healthy subjects and effect of repeated dosing.

M Barza, S Melethil, S Berger, E C Ernst.   

Abstract

Cefamandole nafate, cephapirin, and cephalothin were administered intravenously in crossover fashion to 12 volunteers, in dosages of 2 g every 6 h for 16 doses. Mean peak levels of cefamandole were approximately 50% higher than those of the other agents. The serum concentration curves appeared to decline bi-exponentially, suggesting that a two-compartment model was most applicable for pharmacokinetic analysis; accordingly, the t((1/2)) of cefamandole was significantly longer when the serum peak was omitted from the analysis (0.86 versus 0.73 h, P < 0.05). The half-lives of cephalothin and cephapirin, 0.34 and 0.36 h, respectively, were probably underestimates reflecting the inclusion of distribution-phase values in the calculation. Repeated dosing had no effect on the peak serum levels, half-life, serum clearance, or apparent volume of distribution with one exception: peak serum levels of cephapirin were significantly lower after the sixteenth than after the first dose. Marked variations within a given subject were noted in the half-life and apparent volume of distribution of cefamandole in several instances. Renal clearances of cefamandole exhibited saturation kinetics similar to those of penicillin G.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 984783      PMCID: PMC429764          DOI: 10.1128/AAC.10.3.421

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Pharmacokinetics and clinical use of cephalosporin antibiotics.

Authors:  C H Nightingale; D S Greene; R Quintiliani
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

2.  Penicillin clearance as kidney function test, determinations with and without collection of urine.

Authors:  M PERS
Journal:  Scand J Clin Lab Invest       Date:  1954       Impact factor: 1.713

3.  Clinical pharmacology of cefamandole as compared with cephalothin.

Authors:  I W Fong; E D Ralph; E R Engelking; W M Kirby
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

4.  Activity of cefamandole and other cephalosporins against aerobic and anaerobic bacteria.

Authors:  E C Ernst; S Berger; M Barza; N V Jacobus; F P Tally
Journal:  Antimicrob Agents Chemother       Date:  1976-05       Impact factor: 5.191

5.  Cephapirin: pharmacology in normal human volunteers.

Authors:  J Axelrod; B R Meyers; S Z Hirschman
Journal:  J Clin Pharmacol New Drugs       Date:  1972 Feb-Mar

6.  Pharmacokinetics of cefazolin in normal and uremic subjects.

Authors:  P G Welling; W A Craig; A L Gordon; C M Kunin
Journal:  Clin Pharmacol Ther       Date:  1974-04       Impact factor: 6.875

7.  Penetration of antibiotics into fibrin loci in vivo. II. Comparison of nine antibiotics: effect of dose and degree of protein binding.

Authors:  M Barza; T Samuelson; L Weinstein
Journal:  J Infect Dis       Date:  1974-01       Impact factor: 5.226

8.  Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients.

Authors:  W M Kirby; J B De Maine; W S Serrill
Journal:  Postgrad Med J       Date:  1971-02       Impact factor: 2.401

9.  In vitro activity and pharmacokinetics in patients of cefamandole, a new cephalsoporin antibiotic.

Authors:  N K Shemonsky; J Carrizosa; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1975-12       Impact factor: 5.191

10.  Significant reduction in the incidence of phlebitis with buffered versus unbuffered cephalothin.

Authors:  M G Bergeron; J L Brusch; M Barza; L Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

View more
  14 in total

1.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

Review 2.  Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.

Authors:  W A Craig; P G Welling
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

3.  Penetration of cefamandole, cephalothin, and desacetylcephalothin into fibrin clots.

Authors:  M G Bergeron; B M Nguyen; S Trottier; L Gauvreau
Journal:  Antimicrob Agents Chemother       Date:  1977-12       Impact factor: 5.191

4.  Saturation of the tubular excretion of beta-lactam antibiotics.

Authors:  J W Bins; H Mattie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

5.  Pharmacokinetics of cefotaxime.

Authors:  K P Fu; P Aswapokee; I Ho; C Matthijssen; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

6.  Pharmacokinetics of cefamandole using a HPLC assay.

Authors:  N S Aziz; J G Gambertoglio; E T Lin; H Grausz; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

7.  Pharmacokinetics of cefamandole in osseous tissue.

Authors:  R J Lunke; R H Fitzgerald; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

8.  Absorption and disposition kinetics of amoxicillin in normal human subjects.

Authors:  A Arancibia; J Guttmann; G González; C González
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

Review 9.  Cefuroxime: a review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-04       Impact factor: 9.546

10.  Human pharmacology of cefotaxime (HR 756), a new cephalosporin.

Authors:  R Lüthy; R Münch; J Blaser; H Bhend; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.